Problem
The diagnosis of lung cancer and other diseases of the respiratory system is commonly made in late stages, only through expensive and invasive tests, resulting in a low possibility of treatment and very high human and financial costs for public and private health systems. Lung cancer is the third most prevalent but is nevertheless the most deadly, with an upward trend due to cigarette and vape smoking, microplastic suspended in indoor environments, pollution in outdoor environments and also the incidence of radon gas in buildings. Gold standard exams are available in large centers and are expensive, leaving a rural population and small urban centers unattended.
Solution
Through the development of a disposable, non-electronic and accessible capture device for preservation, transport and expiration analysis containing specific biomarkers, which are analyzed by equipment widely available in hospitals and diagnostic laboratories, but with treatment through a dedicated AI system, not dependent on commercial LLM models, which crosses quantitative and qualitative data from the biomarkers with the patient's profile and history, providing the doctor with a risk score for making decisions regarding observe or deepen the diagnostic mechanisms. The end result is an early, accessible and non-invasive pre-diagnosis, moving the patient from late reactive medicine to predictive and preventive medicine, allowing for the screening of large populations.
Business model
Sale of tests to patients or diagnostic laboratories obtaining reimbursement for FDA code terms based on a medical request, result made available to the doctor, average ticket of US$ 150,00 the US$ 200,00, contra US$ 600,00 of an LDCT exam
Market
We have data from North America - 40 millions of people within the risk group require annual monitoring of the kind we offer, but only 4,5% have access to the gold standard exams. 240. 000 patients are diagnosed with lung cancer every year, half of whom are in late stages, placing a burden on the health systems of 36 billions of dollars annually. (Data from the FDA, American Lung Association, World Cancer Research Fund, and American Cancer Association). Lung cancer is a global problem and its incidence increases year by year due to the problems mentioned above.
Competitors
Bronchoscopy, biopsy with chest perforation, and low-dose computed tomography.
Competitive differentiation
Reduced cost and the possibility of significant margin, scalability, local or global application without the need to change the business model, a non-invasive process that eliminates the need for a clinical environment to perform, a change from late reactive medicine to predictive and preventive medicine.
Entry barrier
International patent already filed, unique approach, ownership of the AI system for qualitative and quantitative analysis, exponential improvement of the system through increased data possession
Traction
No, we are still validating real patients to enter large scale clinical trials